Essentials of daflon 500 mg: From early valve protection to long-term benefits in the management of chronic venous disease

Current Pharmaceutical Design

Volumn 13, Issue 4, 2007, Pages 431-444

  Pascarella, Luigi ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chronic venous disease; Micronized purified flavonoid fraction; Venous hypertension; Venous reflux

Indexed keywords

BETA INTEGRIN; DAFLON; DIOSMIN; GELATINASE A; GELATINASE B; HESPERIDIN; PLACEBO;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; AUTONOMIC DYSFUNCTION; CAPILLARY PERMEABILITY; CELL INTERACTION; CELL PROTECTION; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMPRESSION THERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE ASSOCIATION; DROWSINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; DYSPEPSIA; EXPERIMENTAL MODEL; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERPIGMENTATION; HYPERTENSION; INFLAMMATION; INSOMNIA; LEG EDEMA; LEG ULCER; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; MANAGED CARE; META ANALYSIS; MORBIDITY; NAUSEA; NONHUMAN; PATHOGENESIS; PERIPHERAL VEIN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SKIN ULCER; STOMACH DISEASE; SYSTEMATIC REVIEW; VALVULAR HEART DISEASE; VASCULAR ENDOTHELIUM; VEIN DISEASE; VEIN TONE; VENOUS REFLUX; VERTIGO; VOMITING;

EID: 33947606352     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780162953     Document Type: Review

References (98)

1. Nicolaides AN. Investigation of chronic venous insufficiency; a consensus statement. Circulation 2000; 102: e126-63.
2. Scott TE, LaMorte WW, Gorin DR, Menzoian JO. Risk factors for chronic venous insufficiency: a dual case-control study. J Vasc Surg 1995; 22: 622-8.
3. Takase S, Pascarella L, Bergan J, Schmid-Schönbein G. Venous hypertension, inflammation and valve remodeling. Eur J Vasc Endovasc Surg 2004; 28: 484-93.
4. Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid fraction. A review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs 2003; 63: 71-100.
5. Les Laboratoires Servier. Daflon 500: summary of product characteristics. Available at: http://www.servier.com/pro/phlebologie/ daflon_spc.asp. Accessed June 7, 2006.
6. Katsenis K. Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency. Curr Vasc Pharmacol 2005; 3: 1-9.
7. International Task Force. The management of chronic venous disorders of the leg: an evidence-based report. Phlebology 1999; 14(Suppl 1): 1-126.
8. Fowkes FGR, Evans CJ, Lee AJ. Prevalence and risk factors of chronic venous insufficiency. Angiology 2001; 52(Suppl 1): S5-15.
9. Valencia IC, Falabella A, Kirsner RS, Eaglstein WH. Chronic venous insufficiency and venous leg ulceration. J Am Acad Dermatol 2001; 44: 401-21.
10. Jantet G, and the RELIEF Study Group. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids. Angiology 2002; 53: 245-56.
11. Eklof B, Rutherford RB, Bergan JJ, Carpentier PH, Gloviczki P, Kistner RL, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004; 40: 1248-52.
12. Chiesa R, Marone EM, Limoni C, Volonte M, Schaefer E, Petrini O. Chronic venous insufficiency in Italy: the 24-cities cohort study. Eur J Vasc Endovasc Surg 2005; 30: 422-9.
13. Boisseau M. Mechanisms of onset of chronic venous insufficiency. Phlebolymphology 2003; 41: 161-7.
14. Jawien A. The influence of environmental factors in chronic venous insufficiency. Angiology 2003; 54: S19-31.
15. Evans CJ, Fowkes FGR, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. J Epidemiol Community Health 1999; 53: 149-53.
16. Italian College of Phlebology. Guidelines for the diagnosis and treatment of chronic venous insufficiency. Int Angiol 2001; 20(2 Suppl 2): 1-37.
17. Mózes G, Carmichael SW, Gloviczki P. Development and anatomy of the venous system. In: Gloviczki P, Yao JS Eds. Handbook of Venous Disorders. 2nd ed. New York, NY: Arnold; 2001; 11-24.
18. Caggiati A, Bergan JJ, Gloviczki P, Jantet G, Wendell-Smith CP, Partsch H. for the International Interdisciplinary Consensus Committee on Venous Anatomical Terminology. Nomenclature of the veins of the lower limbs: an international interdisciplinary consensus statement. J Vasc Surg 2002; 36: 416-22.
19. Bergan JJ, Schmid-Schönbein G, Coleridge-Smith P, Nicolaides A, Boisseau M, Eklof B. Chronic venous disease. N Engl J Med 2006; 355: 488-98.
20. Bradbury A, Evans C, Allan P, Ruckley CV, Fawkes FG. What are the symptoms of varicose veins? Edinburgh vein study cross sectional population survey. BMJ 1999; 318: 353-6.
21. Nicolaides AN. From symptoms to leg edema: efficacy of Daflon 500 mg. Angiology 2003; 54: S33-44.
22. Danziger N. Pain in peripheral neuropathies: physiopathology, clinical evaluation and medical management. Rev Neurol 2001; 157: 1565-9 (in French).
23. Wille-Jörgensen P, Jörgensen T, Andersen M, Kirchhoff M. Postphlebitic syndrome and general surgery: an epidemiologic investigation. Angiology 1991; 42: 397-403.
24. Mashiah A, Rose SS, Hod I. The scanning electron microscope in the pathology of varicose veins. Isr J Med Sci 1991; 27: 202-6.
25. Eger SA, Casper SL. Etiology of varicose veins from an anatomic aspect based on dissections of 38 adult cadavers. JAMA 1943; 123: 148-9.
26. Bergan JJ, Schmid-Schönbein GW, Takase S. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500 mg. Angiology 2001; 52: S43-7.
27. Labropoulos N, Giannoukas AD, Delis K, Mansour MA, Kang SS, Nicolaides NN, et al. Where does venous reflux start? J Vasc Surg 1997; 26: 736-42.
28. Corcos L, De Anna D, Dini M, Macchi C, Ferrari PA, Dini S. Proximal long saphenous vein valves in primary venous insufficiency. J Mal Vasc 2000; 25: 27-36.
29. Saharay M, Shields DA, Georgiannos SN, Porter JB, Scurr JH, Coleridge Smith PD. Endothelial activation in patients with chronic venous disease. Eur J Vasc Endovasc Surg 1998; 15: 342-9.
30. Shields DA, Andaz SK, Sarin S, Scurr JH, Coleridge Smith PD. Plasma elastase in venous disease. Br J Surg 1994; 81: 1496-9.
31. Ono T, Bergan JJ, Schmid-Schönbein GN, Takase S. Monocyte infiltration into venous valves. J Vasc Surg 1998; 27: 158-66.
32. Scott HJ, Coleridge Smith PD, Scurr JH. Histological study of white blood cells and their association with lipodermatosclerosis and venous ulceration. Br J Surg 1991; 78: 210-1.
33. Bergan JJ. Leukocytes and venous valve damage in chronic venous disease. Medicographia 2006; 28: 101-8.
34. Takase S, Bergan JJ, Schmid-Schönbein GW. Expression of adhesion molecules and cytokines on saphenous veins in chronic venous insufficiency. Ann Vasc Surg 2000; 14: 427-35.
35. Takase S, Schmid-Schönbein G, Bergan JJ. Leukocyte activation in patients with venous insufficiency. J Vasc Surg 1999; 30: 148-56.
36. Takase S, Lerond L, Bergan JJ, Schmid-Schönbein GW. Enhancement of reperfusion injury by elevation of microvascular pressures. Am J Physiol Heart Circ 2002; 282: H1387-94.
37. Weber C. Novel mechanistic concepts for the control of leukocyte transmigration: specialisation of integrins, chemokines, and junctional molecules. J Mol Med 2003; 81: 4-19.
38. Michiels C, Arnould T, Thibaut-Vercruyssen R, Bouaziz N, Janssens D, Remacle J. Perfused human saphenous veins for the study of the origin of varicose veins: role of the endothelium and of hypoxia. Int Angiol 1997; 16: 134-41.
39. Pascarella L, Schmid-Schonbein GW, Bergan J. An animal model of venous hypertension: the role of inflammation in venous valve failure. J Vasc Surg 2005; 41: 303-11.
40. Jacobs MP, Badier-Commander C, Fontaine V, Benazzoug Y, Feldman L, Michel JB. Extracellular matrix remodeling in the vascular wall. Pathol Biol 2001; 49: 326-32.
41. Badier-Commander C, Jacobs MP, Michel JB. Varicose remodeling (in French). Médecine Thérapeutique 2000; 6: 718-23.
42. Pascarella L, Lulic D, Alsaigh T, Lee J, Kapur V, Schmid Schönbein G, et al. Venous hypertension induced venous insufficiency ameliorated by Daflon 500 mg. Book of abstracts of the tripartite meeting of the European Venous Forum, June 29-July 1, 2006, London UK. Edizioni Minerva Medica, (Turin) 2006; 16.
43. Michiels C, Bouaziz N, Remacle J. Role of the endothelium and blood stasis in the appearance of varicose veins. Int Angiol 2002; 21: 1-8.
44. Michiels C, de Leener F, Arnould T, Dieu M, Remacle J. Hypoxia stimulates human endothelial cells to release smooth muscle cell mitogens: role of prostaglandins and bFGF. Exp Cell Res 1994; 213: 43-54.
45. Eberhardt RT, Raffetto JD. Chronic venous insufficiency. Circulation 2005; 111: 2398-409.
46. Junger M, Steins A, Hahn M, Hafner HM. Microcirculatory dysfunction in chronic venous insufficiency (CVI). Microcirculation 2000; 7: S3-12. Review.
47. Virgini-Magalhaes CE, Porto CL, Fernandes FF, Dorigo DM, Bottino DA, Bouskela E. Use of microcirculatory parameters to evaluate chronic venous insufficiency. J Vasc Surg 2006; 43: 1037-44.
48. Mathura KR, Vollebregt KC, Boer K, De Graaf JC, Ubbink DT, Ince C. comparison of OPS imaging and conventional capillary microscopy to study the human microcirculation. J Appl Physiol 2001; 91: 74-8.
49. Howlader MH, Coleridge-Smith PD. Microangiopathy in chronic venous insufficiency: quantitative by capillary microscopy. Eur J Vasc Surg 2003; 26: 325-31.
50. Ramelet AA. Pharmacologic aspects of a phlebotropic drug in CVI-associated edema. Angiology 2000; 51: 19-23.
51. Coleridge Smith PD. Neutrophil activation and mediators of inflammation in chronic venous insufficiency. J Vasc Res 1999; 36(Suppl 1): 24-36.
52. Takase S, Lerond L, Bergan JJ, Schmid-Schonbein GW. The inflammatory reaction during venous hypertension in the rat. Microcirculation 2000; 7: 41-52.
53. Ramelet AA. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency. Angiology 2001; 52(Suppl 1): S49-56.
54. Coleridge Smith PD, Thomas P, Scurr JH, Dormandy JA. Causes of venous ulceration: a new hypothesis. Br Med J 1988; 296: 1693-5.
55. Pappas PJ, Saito S, Duran WN, Hobson RW. Pathology and cellular physiology of chronic venous insufficiency. In: Cairols MA Ed, Insuficiencia Venosa Cronica. First edition. Barcelona, Spain. Viguera 2002; 113-28.
56. Garner RC, Garner JV, Gregory S, Whattam M, Calam A, Leong D. Comparison of the absorption of micronized (Daflon 500 mg) and non-micronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. J Pharm Sci 2002; 91: 32-40.
57. Cospite M, Dominici A. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form. Int Angiol 1989; 8(4 suppl): 61-5.
58. Bouskela E, Cyrino FZGA, Lerond L. Micronization enhances the protective effect of purified flavonoid fraction on postischemic microvascular injury in the hamster cheek pouch. Int Angiol 2001; 20(Suppl 1): 19.
59. Bouskela E, Cyrino FZGA, Lerond L. Micronization enhances the protective effect of purified flavonoid fraction on postischemic microvascular injury in the hamster cheek pouch. Clin Exp Pharmacol Physiol 2004; 31(3): 159-62.
60. Cova D, De Angelis L, Giavarini F, Palladini G, Perego R. Pharmacokinetics and metabolism of oral diosmin in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1992; 30: 29-33.
61. Messmer K. Daflon 500 mg: expert report on the preclinical documentation. Courbevoie, France: Institut de Recherches Internationales Servier; 1997.
62. Takase S, Delano FA, Lerond L, Bergan JJ, Schmid-Schonbein GW. Inflammation in chronic venous insufficiency: is the problem insurmountable? J Vasc Res 1999; 36(Suppl 1): 3-10.
63. Duhault J, Pillon G. Mécanisme d'action de Daflon 500 mg sur le tonus veineux noradrénergique. Artères Veines 1992; 11: 217-8.
64. Barbe R, Amiel M. Pharmacodynamic properties and therapeutic efficacy of Daflon 500 mg. Phlebology 1992; 7(Suppl 2): 41-4.
65. Ibegbuna V, Nicolaides AN, Sowade O, Leon M, Geroulakos G. Venous elasticity after treatment with Daflon 500 mg. Angiology 1997; 48: 45-9.
66. Shoab SS, Porter J, Scurr JH, Coleridge-Smith PD. Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease - a prospective study. Eur J Vasc Endovasc Surg 1999; 17: 313-8.
67. Shoab SS, Scurr JH, Coleridge-Smith PD. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction: a pilot study. Eur J Vasc Endovasc Surg 1999; 18: 334-8.
68. Shoab SS, Porter JB, Scurr JH, Coleridge-Smith PD. Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease a pilot study. J Vasc Surg 2000; 31: 456-61.
69. Cesarone MR, Laurora G, De Sanctis MT, Belcaro G. Capillary filtration and ankle edema in patients with venous hypertension: effects of Daflon. Angiology 1993; 44: 57-61.
70. Behar A, Lagrue G, Cohen-Boulakia F, Baillet J. Study of capillary filtration by double labelling I131-albumin and Tc99m red cells. Application to the pharmacodynamic activity of Daflon 500 mg. Int Angiol 1988; 7(2 suppl): 35-8.
71. Galley P, Thiollet M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility. Int Angiol 1993; 12: 69-72.
72. Browse NL, Burnand KG. The cause of venous ulceration. Lancet 1982; 2: 243-5.
73. Ener BK. Dorsal pedal venous oximetry for assessing treatment of chronic venous insufficiency: effects of Daflon 500 mg. Vasc Surg 2000; 34: 43-9.
74. Belcaro G, Cesarone MR, De Sanctis MT, Incandela L, Laurora G, Fevrier B, et al. Laser Doppler and transcutaneous oximetry: modern investigations to assess drug efficacy in chronic venous insufficiency. Int J Microcirc Clin Exp 1995; 15(Suppl 1): 45-9.
75. Allegra C, Bartolo Jr M, Carioti B, Carioti B, Cassiani D. An original microhaemorheological approach to the pharmacological effects of Daflon 500 mg in severe chronic venous insufficiency. Int J Microcirc Clin Exp 1995; 15(Suppl 1): 50-4.
76. Struckmann JR. Clinical efficacy of micronized purified flavonoid fraction: an overview. J Vasc Res 1999; 36(Suppl 1): 37-41.
77. Chassignolle J-F, Amiel M, Lanfranchi G, Barbe R. Activité thérapeutique de Daflon 500 mg dans l'insuffisance veineuse fonctionnelle [in French]. J Int Med 1987; 85: 32-7.
78. Tsouderos Y. Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg. Int Angiol 1989; 8(Suppl 4): 53-9.
79. Gilly R, Pillion G, Frileux C. Evaluation of a new venoactive micronized flavonoid fraction (S 5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology 1994; 9: 67-70.
80. Guillot B, Guilhou JJ, de Champvallins M, Mallet C, Moccatti D, Pointel JP. A long-term treatment with a venotropic drug: results on efficacy and safety of Daflon 500 mg in chronic venous insufficiency. Int Angiol 1989; 8(4 Suppl): 67-71.
81. Laurent R, Gilly R, Frilleux C. Clinical evaluation of a venotronic drug in man. Int Angiol 1988; 7(Suppl 2): 39-43.
82. Blume J, Langenbahn H, de Champvallins M. Quantification of edema using the volometer technique; therapeutic application of Daflon 500 mg in chronic venous insufficiency. Phlebology 1992; 7(Suppl 2): 37-40.
83. Danielsson G, Jungbeck C, Peterson K, Norgren L. A randomized controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease. Eur J Vasc Endovasc Surg 2002; 23: 73-6.
84. Glinski W, Chodynicka B, Roszkiewicz J, Bogdanowski T, Lecewicz-Torun B, Kaszuba A, et al. The beneficial augmentative effects of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: an open multicenter, controlled, randomized study. Phlebology 1999; 14: 151-7.
85. Roztocil K, Stvrtinova V, Strjcek J. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency. Int Angiol 2003; 122: 24-31.
86. Guilhou JJ, Dereure O, Marzin L, Ouvry P, Zuccarelli F, Debure C, et al. Efficacy of Daflon 500 mg in venous ulcer healing: a doubleblind, randomized, controlled versus placebo trial in 107 patients. Angiology 1997; 48: 77-85.
87. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg 2005; 30: 198-208.
88. Menyhei G, Acsady G, Hetenyi A, Dubeaux D, Rado G. Chronobiology and clinical activity of Daflon 500 mg in chronic venous insufficiency. Phlebology 1994; 9(Suppl 1): 15-8.
89. Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Drugs Today 1995; 31(Suppl E): 49-55.
90. Misra MC, Parshad R. Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids. Br J Surg 2000; 87: 868-72.
91. Ho Y-H, Tan M, Seow-Choen F. Micronized purified flavonidic fraction compared favorably with rubber band ligation and fiber alone in the management of bleeding hemorrhoids: randomized controlled trial. Dis Colon Rectum 2000; 43: 66-9.
92. Buckshee K, Takkar D, Aggarwal N. Micronized flavonoid therapy in internal hemorrhoids of pregnancy. Int J Gynaecol Obstet 1997; 57: 145-51.
93. Ho Y-H, Foo CL, Seow-Choen F, Goh HS. Prospective randomized controlled trial of a micronized flavonidic fraction to reduce bleeding after haemorrhoidectomy. Br J Surg 1995; 82: 1034-5.
94. Meyer O. Safety of use of Daflon 500 mg confirmed by acquired experience and new research. Phlebology 1992; 7(Suppl 2): 64-8.
95. Jiang ZM, Cao JD. The impact of micronized purified flavonoid fraction for the treatment of acute hemorrhoidal episodes: a prospective, randomized, double blind, placebo-controlled trial in 90 cases. Curr Med Res Opin 2006; 22: 1141-7.
96. Johnston GA. GABA(A) receptor channel pharmacology. Curr Pharm Des 2005; 11(15): 1867-85.
97. Kumazawa Y, Kawaguchi K, Takimoto H. Immunomodulating effects of flavonoids on acute and chronic inflammatory responses caused by tumor necrosis factor alpha. Curr Pharm Des 2006; 12(32): 4271-9.
98. Tassies D. Pharmacogenetics of antithrombotic drugs. Curr Pharm Des 2006; 12(19): 2425-35.